Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?

Osteoporos Int. 2012 Nov;23(11):2681-92. doi: 10.1007/s00198-012-1939-4. Epub 2012 Mar 8.

Abstract

Lifetime supplementation with vitamin K, vitamin D(3), and calcium is likely to reduce fractures and increase survival in postmenopausal women. It would be a cost-effective intervention at commonly used thresholds, but high uncertainty around the cost-effectiveness estimates persists. Further research on the effect of vitamin K on fractures is warranted.

Introduction: Vitamin K might have a role in the primary prevention of fractures, but uncertainties about its effectiveness and cost-effectiveness persist.

Methods: We developed a state-transition probabilistic microsimulation model to quantify the cost-effectiveness of various interventions to prevent fractures in 50-year-old postmenopausal women without osteoporosis. We compared no supplementation, vitamin D(3) (800 IU/day) with calcium (1,200 mg/day), and vitamin K(2) (45 mg/day) with vitamin D(3) and calcium (at the same doses). An additional analysis explored replacing vitamin K(2) with vitamin K(1) (5 mg/day).

Results: Adding vitamin K(2) to vitamin D(3) with calcium reduced the lifetime probability of at least one fracture by 25%, increased discounted survival by 0.7 quality-adjusted life-years (QALYs) (95% credible interval (CrI) 0.2; 1.3) and discounted costs by $8,956, yielding an incremental cost-effectiveness ratio (ICER) of $12,268/QALY. At a $50,000/QALY threshold, the probability of cost-effectiveness was 95% and the population expected value of perfect information (EVPI) was $28.9 billion. Adding vitamin K(1) to vitamin D and calcium reduced the lifetime probability of at least one fracture by 20%, increased discounted survival by 0.4 QALYs (95% CrI -1.9; 1.4) and discounted costs by $4,014, yielding an ICER of $9,557/QALY. At a $50,000/QALY threshold, the probability of cost-effectiveness was 80% while the EVPI was $414.9 billion. The efficacy of vitamin K was the most important parameter in sensitivity analyses.

Conclusions: Lifetime supplementation with vitamin K, vitamin D(3), and calcium is likely to reduce fractures and increase survival in postmenopausal women. Given high uncertainty around the cost-effectiveness estimates, further research on the efficacy of vitamin K on fractures is warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Density Conservation Agents / economics
  • Bone Density Conservation Agents / therapeutic use*
  • Calcium / economics
  • Calcium / therapeutic use
  • Canada / epidemiology
  • Cholecalciferol / economics
  • Cholecalciferol / therapeutic use
  • Cost-Benefit Analysis
  • Dietary Supplements
  • Drug Costs / statistics & numerical data
  • Drug Therapy, Combination
  • Female
  • Health Care Costs / statistics & numerical data*
  • Humans
  • Middle Aged
  • Models, Econometric
  • Osteoporosis, Postmenopausal / complications
  • Osteoporosis, Postmenopausal / drug therapy
  • Osteoporosis, Postmenopausal / economics
  • Osteoporotic Fractures / economics
  • Osteoporotic Fractures / epidemiology
  • Osteoporotic Fractures / etiology
  • Osteoporotic Fractures / prevention & control*
  • Quality of Life
  • Quality-Adjusted Life Years
  • Treatment Outcome
  • Vitamin K 1 / economics
  • Vitamin K 1 / therapeutic use
  • Vitamin K 2 / economics
  • Vitamin K 2 / therapeutic use*

Substances

  • Bone Density Conservation Agents
  • Vitamin K 2
  • Cholecalciferol
  • Vitamin K 1
  • Calcium